Scott Tavernini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Scott Tavernini has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Alessandro Davide Santin
Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, USA
1 shared publication - Andrew R. Martin
Mechanical Engineering and Biomedical Engineering, University of Alberta, Edmonton, AB T6G 1H9, Canada
1 shared publication - David Lewis
Chiesi Limited, Chippenham, UK
1 shared publication - David Scheim
US Public Health Service, Commissioned Corps, Inactive Reserve, Blacksburg, VA 24060, USA
1 shared publication - Jack A. Tuszynski
Dipartimento di Ingegneria Meccanica e Aerospaziale, Politecnico di Torino, Corso Duca degli Abruzzi 24, 10129 Turin, Italy
1 shared publication - Maral Aminpour
Department of Biomedical Engineering, University of Alberta, Edmonton, Canada
1 shared publication
Latest Publications
- Open Access
- 14 July 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (14) , 11449
Computational Prediction of the Interaction of Ivermectin with Fibrinogen
Hypercoagulability and formation of extensive and difficult-to-lyse microclots are a hallmark of both acute COVID-19 and long COVID. Fibrinogen, when converted to fibrin, is responsible for clot formation, but abnormal structural and mechanical clot properties can lead to pathologic thrombosis. Recent experimental evidence suggests that the spike protein (SP) from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may directly bind to the blood coagulation factor fibrinogen and induce structurally abnormal blood clots with heightened proinflammatory activity. Accordingly, in this study, we used molecular docking and molecular dynamics simulations to explore the potential activity of the antiparasitic drug ivermectin (IVM) to prevent the binding of the SARS-CoV-2 SP to fibrinogen and reduce the occurrence of microclots. Our computational results indicate that IVM may bind with high affinity to multiple sites on the fibrinogen peptide, with binding more likely in the central, E region, and in the coiled-coil region, as opposed to the globular D region. Taken together, our in silico results suggest that IVM may interfere with SP–fibrinogen binding and, potentially, decrease the formation of fibrin clots resistant to degradation. Additional in vitro studies are warranted to validate whether IVM binding to fibrinogen is sufficiently stable to prevent interaction with the SP, and potentially reduce its thrombo-inflammatory effect in vivo.
- 14 July 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (14) , 11449
Open AccessComputational Prediction of the Interaction of Ivermectin with Fibrinogen
Hypercoagulability and formation of extensive and difficult-to-lyse microclots are a hallmark of both acute COVID-19 and long COVID. Fibrinogen, when converted to fibrin, is responsible for clot formation, but abnormal structural and mechanical clot properties can lead to pathologic thrombosis. Recent experimental evidence suggests that the spike protein (SP) from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may directly bind to the blood coagulation factor fibrinogen and induce structurally abnormal blood clots with heightened proinflammatory activity. Accordingly, in this study, we used molecular docking and molecular dynamics simulations to explore the potential activity of the antiparasitic drug ivermectin (IVM) to prevent the binding of the SARS-CoV-2 SP to fibrinogen and reduce the occurrence of microclots. Our computational results indicate that IVM may bind with high affinity to multiple sites on the fibrinogen peptide, with binding more likely in the central, E region, and in the coiled-coil region, as opposed to the globular D region. Taken together, our in silico results suggest that IVM may interfere with SP–fibrinogen binding and, potentially, decrease the formation of fibrin clots resistant to degradation. Additional in vitro studies are warranted to validate whether IVM binding to fibrinogen is sufficiently stable to prevent interaction with the SP, and potentially reduce its thrombo-inflammatory effect in vivo.
- 1 April 2018
- Published by Elsevier in Journal of Aerosol Science
- Vol. 118, 14-21
Scaling an idealized infant nasal airway geometry to mimic inertial filtration of neonatal nasal airways
- 1 April 2018
- Published by Elsevier in Journal of Aerosol Science
- Vol. 118, 14-21
Scaling an idealized infant nasal airway geometry to mimic inertial filtration of neonatal nasal airways